Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04633889 · ClinicalTrials.gov registry record · Phase 2
Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
A Phase 2 study of Acute Kidney Injury, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
- 3
- Study locations
NCT04633889 is a Phase 2 study of Acute Kidney Injury that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 320 participants, below the 2,327-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT04633889, a Phase 2 study of Acute Kidney Injury, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
- 3
- Study locations
Study Summary
Multiple lines of evidence support a central role of iron in causing acute kidney injury (AKI), including the finding that prophylactic administration of iron chelators attenuates AKI in animal models. Patients undergoing cardiac surgery may be particularly susceptible to iron-mediated kidney injury due to the profound hemolysis that often occurs from cardiopulmonary bypass. The investigators will test in a phase 2, randomized, double-blind, placebo-controlled trial whether prophylactic administration of deferoxamine decreases the incidence of AKI following cardiac surgery.
Conditions Studied
Interventions
- DRUG Normal saline
- DRUG Deferoxamine
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04633889
The ClinicalTrials.gov registry entry for NCT04633889 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,327-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (86% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.
NCT04633889 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04633889 about?
NCT04633889 is a clinical study titled "Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury". Multiple lines of evidence support a central role of iron in causing acute kidney injury (AKI), including the finding that prophylactic administration of iron chelators attenuates AKI in animal models. Patients undergoing cardiac surgery may be particularly susceptible to iron-mediated kidney injury...
What is the current status of trial NCT04633889?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2021-04-13. Estimated completion is 2026-03-01.
What conditions does trial NCT04633889 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT04633889?
The interventions under investigation include: Normal saline (DRUG), Deferoxamine (DRUG).
Who is sponsoring clinical trial NCT04633889?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04633889 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.